SINGAPORE, May 05, 2025 — Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology firm focused on creating and selling products for chronic wound care, infertility solutions, and cosmeceuticals, announced the completion of its in-vitro fertilization (“IVF”) media production facility in Singapore on April 6, 2025. The facility has also secured ISO 13485 certification and a dealer license.

The ISO 13485 certification, granted by the United Kingdom Accreditation Service (“UKAS”), a member of the International Accreditation Forum (“IAF”), confirms that Cuprina’s quality management system at the facility adheres to globally recognized standards for medical device manufacturing. The dealer license, issued by the Singapore Health Sciences Authority (HSA), provides the necessary legal permissions for businesses involved in activities like manufacturing, importing, or distributing medical devices.

The facility, built in collaboration with Singapore-based medtech company Ferti-Craft Pte Ltd. (“Ferti-Craft”), will produce 14 different IVF media products. These products will contain the nutrients, electrolytes, amino acids, and other essential components required to facilitate the fertilization of sperm and eggs in a laboratory setting.

Cuprina and Ferti-Craft will work together to compile and submit the required regulatory documentation to the Singapore Health Sciences Authority (“HSA”) to seek approval for the 14 IVF media product SKUs. The project aims to gain HSA approval for commercial sales before the fourth quarter of 2026.

Ferti-Craft will be in charge of obtaining all the necessary documentation and testing certificates required by HSA. They will also manage the selection and logistics of all raw materials needed for the production of these SKUs. Additionally, Ferti-Craft will contribute intellectual property, expertise in human assisted reproductive technology (“ART”), and production know-how for the preparation of these SKUs.

Pending the receipt of necessary regulatory approvals, commercial production at the facility is anticipated to begin by the fourth quarter of 2026. Ferti-Craft anticipates that initial sales will primarily be in Singapore, followed by expansion into select ASEAN countries, the Middle East, and other international markets.

“We are very excited to be collaborating with Ferti-Craft on this IVF media production facility, the first of its kind in Singapore to be established by a Singapore company,” said Cuprina chief executive David Quek. “Our previous set-up of ISO 13485-compliant facilities in connection with our MEDIFLY live maggot wound care therapy has, we believe, provided us with the experience and expertise necessary to build and manage such facilities and ensure they meet production output on a timely schedule.”

Ferti-Craft co-founder Jai Thampi added, “As the Singapore developer of IVF media, we wanted to collaborate with a trusted and established company with a facility that meets international standards. Cuprina’s overall experience and flexibility to scale their facility to meet our stringent requirements gave us the confidence to ink this strategic agreement.”

According to Global Market Insights, the total ART market was valued at $34.7 billion in 2023. Driven by increasing infertility rates, growing acceptance of ART technologies, and other factors, the market is projected to grow at an annual rate of 6.9%, reaching $62.8 billion by 2032.

About Cuprina Holdings (Cayman) Limited
We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit .

About Ferti-Craft Pte Ltd.
Ferti-Craft is a Singapore-based medtech company innovating world-class medical devices that meet international standards for the human Assisted Reproductive Technology (ART) industry, with special focus on In vitro fertilization (IVF) and Intrauterine insemination (IUI) treatments. Our mission is to make our medical devices available globally at hospitals and fertility clinics. We blend together decades of clinical expertise and cutting-edge technologies to help make dreams come true for the many couples yearning for a child. For more information, please visit .

FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email:

Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email:

“`